Polynucleotides High Purification Technology: A Real-World Prospective Study in a Hospital Outpatient Setting Supports PN HPT as a Regenerative Medicine Option for Acne Scar Management
Clinical, Cosmetic and Investigational Dermatology · 2026-08 · Volume 19 · 1-11
DOI: 10.2147/ccid.s621545 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-08. Verfasst von Emanuele Bartoletti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, Servizio Ambulatoriale di Medicina Estetica e del Benessere Psicofisico nella Patologia (SAMEst), Gemelli Isola Hospital, Rome…. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
A double-blind, placebo-controlled trial demonstrated that Polynucleotides High Purification Technology (PN HPT) are an effective regenerative medicine treatment for moderate-to-severe atrophic post-acne scars. This prospective cohort study combined PN HPT with hyaluronic acid to confirm the previously reported highly controlled results in real-world outpatients.
Methods
The study, conducted in a hospital outpatient setting, included 30 women and men aged 20 to 60 years who sought treatment for moderate-to-severe post-acne atrophic scars (Goodman-Baron grades 3-4). Treatment: PN HPT 10 mg/mL, hyaluronic acid sodium salt 10 mg/mL, and mannitol in an isotonic, buffered, viscoelastic hydrogel (CE-marked Class III Newest® medical device, Mastelli Srl, Sanremo, Italy; 30 microdrops or 0.1-0.2 mL per injection site) at baseline (T0) and after 2, 4, and 6 weeks (T1, T2, and T3, respectively). Primary endpoint: Blinded assessment of changes in scar characteristics using the 4-grade Goodman-Baron scale for acne scar assessment at post-treatment follow-up visits after three (FU3) and six months (FU6), compared to T0. Secondary endpoints: Optional objective assessment of skin quality in scarred skin surface areas (using Antera 3D or QuantifiCARE) and aesthetic impact assessed by the Global Aesthetic Improvement Scale (GAIS) questionnaire.
Results
The mean scar area decreased from 106.6±26.34 to 93.1±20.98 at FU6 (p=0.0012; 25 of 30 subjects). The mean Goodman-Baron scores declined by 18.8% at FU3 (p=0.0012) and by 22.12% at FU6 (p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Trial Center, Servizio Ambulatoriale di Medicina Estetica e del Benessere Psicofisico nella Patologia (SAMEst), Gemelli Isola Hospital, Rome, Italy.
- Medical Statistics Consultant, Locarno, Switzerland.
ORCID-Profile: Emanuele Bartoletti
Zitieren
APA
Bartoletti, E., Trocchi, G., Fiorini, I., Saccà, O., Di Castro, M., D'Addario, G., & Prussia, C. (2026). Polynucleotides High Purification Technology: A Real-World Prospective Study in a Hospital Outpatient Setting Supports PN HPT as a Regenerative Medicine Option for Acne Scar Management. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-11. https://doi.org/10.2147/ccid.s621545
Vancouver
Bartoletti E, Trocchi G, Fiorini I, Saccà O, Di Castro M, D'Addario G, et al. Polynucleotides High Purification Technology: A Real-World Prospective Study in a Hospital Outpatient Setting Supports PN HPT as a Regenerative Medicine Option for Acne Scar Management. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-11. doi:10.2147/ccid.s621545
BibTeX
@article{Bartoletti2026,
author = {Bartoletti, Emanuele and Trocchi, Gloria and Fiorini, Ilenia and Saccà, Ornella and Di Castro, Myriam and D'Addario, Giulia and Prussia, Carolina},
title = {Polynucleotides High Purification Technology: A Real-World Prospective Study in a Hospital Outpatient Setting Supports PN HPT as a Regenerative Medicine Option for Acne Scar Management},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
volume = {Volume 19},
pages = {1--11},
doi = {10.2147/ccid.s621545}
}
EUVIMED